PCV50 COSTS OF THE DIAGNOSIS OF RENAL ARTERY STENOSIS  by van Helvoort-Postulart, D et al.
662 Abstracts
OBJECTIVE: To estimate the cost-effectiveness of citico-
line in comparison to conventional therapy for the treat-
ment of patients with acute ischemic stroke. METHODS:
Decision tree analysis incorporating economic data and
results from alternative systematic reviews of effective-
ness. Data on effectiveness were obtained from a system-
atic review performed by the Cochrane Stroke Review
Group (CSRG) and a pooled analysis of primary data
from clinical trials sponsored by the Ferrer Group.
Resource use was obtained from a panel of experts based
in 5 Spanish hospitals. Unit costs were obtained from the
centres included in the study and from prices published
by the Spanish health care authorities. Two alternative
scenarios were considered: hospitalised patient and hos-
pitalised patient with ambulatory follow-up. Sensitivity
analysis of the key variables included was performed. The
time horizon for the study was 12 weeks. RESULTS: Even
in the most unfavourable scenario analysed, citicoline
proved to be an efﬁcient treatment option in patients with
acute ischemic stroke. Citicoline led to increases in the
proportion of patients without discapacity of between
5% and 10%, compared to conventional treatment.
Based on the efﬁcacy ﬁgures reported by the CSRG, the
cost per patient treated with citicoline was €3026.12
when only hospitalisation was taken into account, while
the equivalent cost per patient receiving placebo was
€3127.34. When the costs of ambulatory follow-up were
added, the cost per patient increased to €3663.50 in 
the citicoline group and €3795.90 in patients receiving
placebo. CONCLUSION: Citicoline is an effective and
efﬁcient treatment alternative in the management of
stroke patients, in all of the scenarios analysed.
PCV50
COSTS OF THE DIAGNOSIS OF RENAL ARTERY
STENOSIS
van Helvoort-Postulart D1, Dirksen CD1,
van Engelshoven JM1, Hunink MG2
1University Hospital Maastricht, Maastricht, Limburg,
Netherlands; 2Erasmus Medical Center Rotterdam, Rotterdam,
Netherlands
OBJECTIVES: Timely detection of renal artery stenosis
(RAS) is important as it may cause renovascular hyper-
tension and renal impairment. In the Renal Artery Diag-
nostic Imaging Study in Hypertension (RADISH), 402
patients suspected of having RAS were submitted to 
computed tomographic angiography (CTA), magnetic 
resonance angiography (MRA) and digital subtraction
angiography (DSA), in order to investigate the diagnostic
performance of CTA and MRA. Providing policy makers
and clinicians with information about the costs associated
with applying different diagnostic imaging strategies for
detecting RAS is important. Therefore, also a compara-
tive short-term cost analysis was performed. METHODS:
The analysis involved three diagnostic strategies: 1) direct
DSA; 2) CTA ± DSA, and 3) MRA ± DSA. Strategies 2
and 3 included DSA as the gold standard to conﬁrm the
diagnosis. After a negative CTA or MRA test result no
further tests were performed. The cost calculations were
performed from the societal perspective. Data were ana-
lyzed using a decision model, combining original patient
data and medical literature data. Short-term costs were
deﬁned as costs occurring during the ﬁrst year after treat-
ment, including the diagnostic work-up and revascular-
ization procedure. RESULTS: The strategy, whereby
patients are referred for DSA only in case of a positive
CTA test result was the least costly option (€2286), fol-
lowed by MRA ± DSA and direct DSA (€2598 and €3695,
respectively). CONCLUSIONS: Considered from the cost
perspective, CTA followed by DSA only in case of a pos-
itive test result is the strategy of choice. However, the cost
consequences of false negative test results were not con-
sidered since these effects generally reveal in the long
term. Also, health beneﬁts in terms of quality of life 
and life expectancy were not included in the analysis.
Therefore, a cost-effectiveness Markov model, including
short and long term costs and health effects, is currently
built.
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OBJECTIVES: In the Irbesartan in Diabetic Nephropa-
thy Trial (IDNT), treatment with irbesartan demonstrated
23% and 20% reductions in the combined endpoint 
of doubling of serum creatinine (DSC), end-stage renal
disease (ESRD) or death in patients with hypertension,
type 2 diabetes, and overt nephropathy compared to
amlodipine and control respectively. A simulation model
was developed to project long-term cost consequences of
the IDNT in Hungary. METHODS: A Markov model
simulated progression from nephropathy to DSC, ESRD,
and death in patients with hypertension, type 2 diabetes
and overt nephropathy. Treatment-speciﬁc probabilities
were derived from IDNT. Hungarian-speciﬁc ESRD-
related data were retrieved from local databases. Delay in
onset of ESRD, life expectancy and mean lifetime costs
were calculated for patients with baseline age 59 years.
Future costs were discounted at 5% per annum, and clin-
ical beneﬁts were discounted at 0% and 5% per annum.
Extensive sensitivity analyses were performed. RESULTS:
Onset of ESRD was delayed with irbesartan by 1.41 and
1.35 years versus amlodipine and control respectively.
